Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$11.6M | -$28.9M | -$26.3M | -$55.2M | -$65.4M | -$41.8M | -$51.2M | -$25.4M | -$25.5M |
| EPS (diluted) | -$0.52 | -$0.86 | -$0.52 | -$0.67 | -$0.73 | -$6.80 | -$227.43 | -$36.38 | -$10.41 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.2M | -$23.2M | -$21.6M | -$33.9M | -$43.3M | -$32.3M | -$44.6M | -$36.0M | -$22.0M |
| Capital expenditures | $13.0K | $329K | $102K | $79.0K | $212K | $24.0K | $29.0K | $5.00K | $0.00 |
| Free cash flow | -$10.2M | -$23.5M | -$21.7M | -$34.0M | -$43.5M | -$32.3M | -$44.6M | -$36.0M | -$22.0M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.6M | $15.3M | $79.8M | $117M | $39.1M | $37.0M | $9.25M | $6.15M | $935K |
| Total assets | $12.0M | $16.9M | $100M | $126M | $82.5M | $51.0M | $13.0M | $10.1M | $10.0M |
| Total liabilities | — | $2.79M | $6.55M | $7.35M | $8.29M | $13.3M | $15.9M | $14.7M | $37.2M |
| Shareholders' equity | $10.2M | $14.1M | $93.9M | $119M | $74.2M | $37.7M | -$2.90M | -$4.54M | -$27.2M |
| Retained earnings | -$247M | -$276M | -$302M | -$357M | -$423M | -$464M | -$516M | -$541M | -$566M |
| Shares (wtd avg diluted) | 27.5M | 38.2M | 76.1M | 88.9M | 89.1B | 6.15M | 225K | 699K | 2.45M |
Every figure is extracted from Aptose Biosciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.